Next Article in Journal
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Racial/Ethnic Disparities in Prostate Cancer 5-Year Survival: The Role of Health-Care Access and Disease Severity
Previous Article in Journal
Immunotherapy for Recurrent Glioma—From Bench to Bedside
Previous Article in Special Issue
Risk of Intraepithelial Neoplasia Grade 3 or Worse (CIN3+) among Women Examined by a 5-Type HPV mRNA Test during 2003 and 2004, Followed through 2015
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 13
10.3390/cancers15133422
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study

by
Marco Siringo
1,2,*,
Gabriella Gentile
1,
Salvatore Caponnetto
1,
Isabella Sperduti
3,
Daniele Santini
4,
Enrico Cortesi
1 and
Alain Jonathan Gelibter
1,*
1
Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy
2
Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, 28041 Madrid, Spain
3
Department of Biostatistics Unit, IRCCS—Regina Elena National Cancer Institute, 00144 Rome, Italy
4
Medical Oncology Unit A, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy
*
Authors to whom correspondence should be addressed.
Cancers 2023, 15(13), 3422; https://doi.org/10.3390/cancers15133422
Submission received: 17 May 2023 / Revised: 12 June 2023 / Accepted: 28 June 2023 / Published: 30 June 2023
(This article belongs to the Special Issue Feature Paper in Section “Cancer Epidemiology and Prevention” in 2022–2023)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

ALK-rearranged non-small cell lung cancer treatment has radically changed in the last few years thanks to the development of ALK inhibitors, which clearly improved survival. To our knowledge, even though many studies correlate body mass index (BMI) with lung cancer immunotherapy, conflicting results have emerged in non-smoker patients treated with other drugs. Indeed, it is unclear whether body size variables and metabolism could affect ALK-inhibitor efficacy. The aim of this retrospective study is to correlate BMI status with survival outcomes in patients treated with commonly used ALK inhibitors in different lines of treatment. We observed that BMI status could impact survival outcomes, particularly in patients treated with Alectinib as the first line. Further prospective studies should examine this interesting phenomenon.

Abstract

No evidence exists as to whether body mass index (BMI) impairs clinical outcomes from ALK inhibitors (ALKi) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Retrospective data of patients affected by metastatic ALK-rearranged NSCLC treated with ALKi were collected. We divided patients into “low- BMI” (≤25 kg/m2) and “high- BMI” (>25 kg/m2) categories and correlated them with overall survival (OS) and progression-free survival (PFS). We included 40 patients treated with ALKi. We observed a 3-year OS of 81.5% in high-BMI vs. 49.6% in low-BMI categories (p = 0.049); the 3-year first-line PFS was superior in high-BMI vs. low-BMI patients (47% vs. 19%, p = 0.019). As expected, patients treated with Alectinib had a 55.6% 3-year PFS vs. 7.1% for others treated with ALKi (p = 0.025). High-BMI was associated with a 100% 3-year PFS rate vs. 25.4% in low-BMI Alectinib patients (p = 0.03). BMI was independently correlated with first-line PFS and OS at multivariate analysis with PS (HR 0.39, CI 95% 0.16–0.96, p = 0.042; HR 0.18, CI 95% 0.05–0.61, p = 0.006). High-BMI was associated with higher efficacy in ALK-rearranged patients. These results are particularly exciting for Alectinib and could be correlated to mechanisms that should be investigated in subsequent prospective studies.

1. Introduction

Lung cancer is the leading cause of cancer-related death with a mortality rate of 18.4%. It is the first in men and second in women worldwide, representing the cancer type with the lowest five-year survival rate [1].
Tobacco smoking remains the leading cause, but several other factors have been described as risk factors for lung cancer, including exposure to asbestos, arsenic, radon, and polycyclic aromatic hydrocarbons unrelated to tobacco. In any case, an increased rate of NSCLC diagnoses was observed in non-smokers [2,3].
Accordingly, patients affected by NSCLC without the smoking relationship are considered a different entity because a large number of molecular and genetic mutations could be identified. On this basis, the oncogene-addicted NSCLC population is currently treated with targeted therapies discovered in the last few years [4].
ALK rearrangement is detectable in 2–7% of the lung cancer population. Notably, it is most common in specific categories of patients such as women, non-smokers or light smokers, young people, those with adenocarcinoma histology (often with a signet ring or acinar features), and the Asiatic population [5,6,7].
Moreover, 70% of the ALK-rearranged population develops central nervous system (CNS) metastasis, while almost 30% of patients, at the time of diagnosis, contribute significantly to the improvement of morbidity during their disease course [8].
Small-molecule tyrosine kinase inhibitors (TKIs) that target ALK have been introduced in the last 10 years, leading to improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in patients with ALK-rearranged NSCLC in various clinical trials [9].
The phase III Alex trial compared Alectinib (a second-generation ALK TKI) with Crizotinib (a first-generation ALK TKI), showing a median PFS (mPFS) of 34.8 months, an ORR of 83%, an intracranial response rate of 81%, and a 5-year OS rate of 62.5% [10,11].
Moreover, Brigatinib yielded similar results in the phase III ALTA 1L with mPFS of 24 months, ORR of 74%, 27.9 months of median intracranial duration of response in patients with measurable brain metastases at baseline, and a 3-year intracranial PFS rate of 31%, compared to Crizotinib [12].
Lorlatinib is a third-generation ALK inhibitor that can overcome the secondary resistance mutations that emerge after treatment with first-generation and second-generation ALK inhibitors, and it shows better intracranial activity than Crizotinib. A phase II trial demonstrated an ORR of 47% and 39% in patients treated with Lorlatinib and at least one ALK inhibitor and one or more ALK TKIs, respectively [13].
Recently, a phase III Crown trial compared Lorlatinib to Crizotinib in untreated patients and demonstrated a PFS at 12 months of 78% vs. 39%, ORR of 76% vs. 58%, and an intracranial response rate of 82% vs. 23%, respectively [14].
Based on these results, ALK TKIs have become the standard regimen for patients with advanced NSCLC harboring an ALK rearrangement. Alectinib, Brigatinib, and Lorlatinib are the preferred options but, in the absence of head-to-head comparisons, the optimal choice for first-line therapy in ALK-rearranged lung cancer remains unclear [15].
In recent years, obesity has become a public health problem because of high incidence all around and correlated comorbidities such as hypertension, hyperlipidemia, and hyperglycemia together, constituting metabolic syndrome (MS) [16].
Obesity has long been associated with worse cancer outcomes probably because of systemic physiologic alterations such as higher insulin resistance, chronic inflammation, and abnormal nutrient homeostasis, which may contribute to oncogenic transformations [17,18].
BMI (body mass index) has commonly been used as a surrogate indicator of MS and is calculated as weight in kilograms divided by height in meters squared. BMI association with cancer has been widely studied, showing conflicting results. Indeed, breast, ovarian, and colorectal cancer are associated with high mortality in obese patients while recent studies have shown a possible positive correlation between BMI and lung cancer survival. This phenomenon is called the “obesity paradox”. Nevertheless, poor health status associated with nutritional deficiency and consequent weight loss could contribute [19,20,21,22].
Moreover, lung cancer patients with higher BMI and receiving immune checkpoint inhibitors (ICIs) had better outcomes probably because of increased adipose tissue that could help to regulate immune homeostasis, constituting a trigger for immune response; in retrospective studies, the median time to treatment failure and PFS were significantly longer in overweight/obese patients compared with non-overweight patients in 976 patients affected by NSCLC treated with ICIs. Similarly, higher baseline BMI resulted in an increased ORR and PFS in NSCLC patients treated with Pembrolizumab as a first-line treatment (962 patients) and not with chemotherapy (426 patients) [23,24].
On the other hand, conflicting results emerged in the analysis of the correlation between BMI and outcomes in the EGFR mutated NSCLC population. In a real-world study with patients treated with second-generation EGFR TKIs, high-BMI correlated positively with first-line PFS, primarily in men. These results are not confirmed in the EGFR population treated with second-line Osimertinib, where BMI did not or even negatively influence survival outcomes [25,26,27].
Here, we present the clinical outcomes analysis of patients affected by metastatic NSCLC treated with ALK inhibitors according to baseline BMI, evaluated at the time of metastatic status.

2. Materials and Methods

2.1. Study Design

We conducted a retrospective observational study at Sapienza University of Rome at Policlinico Umberto 1, Oncologia B Department to evaluate the efficacy of anti-ALK treatment and clinical predictive correlations.
Patients were considered eligible for this study if they had a histological or cytological diagnosis of stage IV NSCLC according to the American Joint Committee on Cancer (AJCC) and ALK rearrangement tested with next generation sequencing (NGS), fluorescent in situ hybridization (FISH), or immunochemistry (IHC).
Patients without at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were excluded.
We collected patients’ data, including age at diagnosis, gender, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at the time of first-line treatment, smoking status, clinical staging, tumor histology, presence of central nervous system (CNS) metastasis, and the total number of metastases. At the same time, we analyzed the presence of comorbidities focusing on cardiac and renal diseases and diagnosis of diabetes mellitus type 2 associated with the evaluation of concomitant medications. No analytical data were collected because they were not available in all populations at the time of diagnosis.

2.2. Classifications

Patients were divided according to smoking status: current smoker, former smoker (if they had smoked less than 10 pack years with smoking cessation time superior to 15 years), and never been a smoker (if they had smoked less than 100 cigarettes in their lifetime history).
Moreover, we calculated BMI status using the weight/height2 formula (kg/m2) and divided patients into two categories: BMI ≤ 5 mg/m2 (called “low-BMI”) and BMI > 25 kg/m2 (called “high-BMI”). This dual division was necessary to distinguish low–normal and overweight/obese patients at the time of metastatic status.
Patients received at least one ALK inhibitor between Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, but also in some rare cases, patients received platinum-based chemotherapy or ICIs in different lines of the metastatic setting. Patients who experienced death or progression of disease before radiographic evaluation were excluded.

2.3. Statistical Analysis

We reported continuous variables as median and range, and categorical variables as count and percentage. Progression-free survival (PFS) was defined as the time from treatment initiation until disease progression or last contact without progression disease; overall response rate (ORR) was defined as the portion of patients experiencing an objective response (complete or partial response) as best response to treatment; and overall survival (OS) was defined as the time between the start of first-line treatment and death for any cause or last contact. We estimated the OS and PFS with the Kaplan–Meier survival curves. The log-rank test was used to assess differences between groups. The median period of follow-up was calculated according to the reverse Kaplan–Meier method.
The correlation between ORR and other variables was examined by a binary logistic regression model. Univariate and multivariate Cox models were used to compare the clinical, biological, and pathological characteristics of PFS and OS. Median OS and PFS were reported with 95% confidence intervals (CIs). Significance was defined at p ≤ 0.05 level. Statistical analyses were performed using IBM SPSS Statistics version 23 (IBM, Armonk, NY, USA).

3. Results

3.1. Patients Characteristics

A total of 40 patients treated with ALKi from April 2013 to November 2022 were identified. The median follow-up was 47 months.
A summary of all clinicopathological characteristics of the study population is displayed in Table 1.
The majority of patients (62.5%) were female, and the median age at diagnosis was 63 years.
In total, 32% of the population were PS0, 62,5% were PS1, and 5% were PS2. All patients suffered from adenocarcinoma, stage IV disease, or postoperative recurrence, according to the American Joint Committee on Cancer (AJCC). The median number of metastases was four; 80% and 50% of patients had visceral and brain metastasis, respectively, while 67% had more than three metastases. More than half of patients were non-smokers (52%), while 30% were former or light smokers. BMI was higher than 25 mg/m2 in 37.5%, with few patients affected by diabetes mellitus type 2 (DM2) (only seven) and, consequently, four patients received metformin. In addition, 47% of patients received steroids at diagnosis, and 40% received antiepileptic drugs.
Cardiac and renal comorbidities were detected in almost 13% of the population who were examined.
Out of all patients, 47% (7/15) were PS0 at diagnosis in the overweight/obese population, while 32% (8/25) were underweight/normal patients.
ALKi were evaluated in different metastatic lines; the most used was Alectinib, received in 23, 9, and 2 patients in first-, second-, and third-line treatment, respectively.
In total, 57.5% and 85.5% of patients did not receive second- and third-line treatment. A small percentage of patients did not receive anti-ALK inhibitors as a first-line treatment but rather chemotherapy and immunotherapy (three and two patients, respectively) because of subsequent diagnosis of ALK rearrangement.

3.2. Association between BMI and Outcomes

We grouped patients according to BMI status. We discovered an increased OS in patients with high-BMI compared with low-BMI, with a 3-year OS of 81.5% vs. 49.6%, and an mOS of 74 months (CI 95% 35–74 months) vs. 35 months (CI 95% 9–62 months), respectively (p = 0.049). mOS in the overall population was 62 months (CI 95% 35–74 months) (Figure 1a).
The PFS of first-line treatment, analyzing the population according to BMI status, was increased in high-BMI patients, with a 3-year PFS of 47% (mPFS 30 months, CI 95% 15–41 months) compared with 19% (mPFS 12 months, CI 95% 4–48 months) of the low-BMI population (p = 0.019); mPFS in the overall population was 22 months (CI 95% 13–30, 3 years PFS 30.3%) (Figure 1b).
If the two patients with PS2 were removed from the analysis, first-line PFS continued to be superior in the high-BMI group (p = 0.032), while OS was not statistically significantly correlated with BMI status (p = 0.056).
As expected, when we compared Alectinib treatment with other anti-ALK treatments, we discovered a higher 3-year PFS rate [55.6% vs. 7.1%, mPFS 41 months (CI 95% 12–41) vs. 12 months (CI 95% 4–48), respectively, p = 0.025] (Figure 2).
Interestingly, patients who received Alectinib as first-line treatment had a 3-year PFS rate of 100% if they were high-BMI versus only 25.4% in the low-BMI group (mPFS not estimated vs. 12 months, CI 95% 3–22 months, p = 0.03) (Figure 3). BMI positively correlated with ORR in the course of Alectinib as a first-line treatment (OR 1.71, CI 95%: 1.080–2.70, p = 0.022) (Figure 4). Notably, PFS was positively influenced by the interaction between BMI and Alectinib [HR 0.065, CI 95% 0.006–0.74, p = 0.028].
PFS and OS were not significantly influenced in univariate and multivariate analysis by clinical variables such as age at the metastatic stage, number of metastases, visceral metastasis, brain metastasis, and smoking status (Table 2).
At univariate analysis, high-BMI positively influenced PFS (HR 0.35, CI 95% 0.15–0.84, p = 0.019) and OS (HR 0.27, CI 95% 0.09–0.80, p = 0.020); at the same time, ECOG PS0 correlated with PFS (HR 0.22, CI 95% 0.07–0.65, p = 0.007) and OS (HR 0.21, CI 95% 0.06–0.71, p = 0.013).
Furthermore, at multivariate analysis, BMI and PS were independent factors at PFS (BMI high vs. low: HR 0.39, CI 95% 0.16–0.96, p = 0.042; PS0 vs. PS 1–2: HR 0.24, CI 95% 0.08–0.73, p = 0.012) and OS (BMI high vs. low: HR 0.18, CI 95% 0.05–0.61, p = 0.006; PS0 vs. PS1-2 HR 0.15, CI 95% 0.04–0.55, p = 0.014).
Treatment regimens different from Alectinib were associated with a shorter first-line PFS at univariate analysis (HR 2.35, CI 95% 1.05–5.25, p = 0.038) but not at multivariate analysis adjusted by PS and BMI (HR 2.01, CI 95% 0.89–4.5, p = 0.094).
No significative difference between Crizotinib and Alectinib as first-line treatment were observed (HR 2.07, CI 95% 0.85–5.02, p = 0.10).
In conclusion, we found some interesting clinical trends. Patients not treated with Alectinib who were grouped as high-BMI had a 3-year PFS of 0% compared to 13.3% of patients with a low BMI [mPFS 15 months (CI 95% 3–30) vs. 10 months (CI 95% 3–48), p = 0.86] (Figure 5). All patients who experienced a radiographic complete response (CR) (10 patients) in the course of ALK inhibitors as a first-line treatment (nine with Alectinib and one with Crizotinib) and as a second-line treatment (two with Alectinib) belong to the high-BMI category. All of them had PFS superior to 34 months at the time of last follow-up. Patients treated with metformin because of diabetes mellitus had a high BMI and a PFS superior to 34 months with Alectinib therapy. The presence of smoking history, collected in a large proportion of patients (48%), did not significatively influence ORR to first-line Alectinib treatment, although this was without statistical significance (OR 2.22, CI 95% 0.37–13.5, p = 0.38).

4. Discussion

To our knowledge, the present analysis is the first and only study that evaluates a possible positive correlation between BMI status and outcomes with ALK inhibitors treatment. Indeed, we divided the ALK-rearranged NSCLC population into two major groups, identifying a basal BMI of 25 mg/mq as a cut-off, as previously achieved in other studies [24,25,26].
Interestingly, overweight/obese patients had a better first-line PFS and OS and at the same time, if treated with first-line Alectinib, had a longer PFS compared to low/normal-BMI patients. Consequently, we believe that we have identified for the first time that BMI status could be a clinical predictive biomarker with Alectinib therapy.
However, the biological basis of the association is just beginning to be understood. ALK inhibitors were demonstrated to drastically increase lung cancer survival, but there is a lack of clinical and molecular prognostic and predictive biomarkers [28].
Zhou et al. observed that the BMI decreased the risk of lung adenocarcinoma after adjustment of smoking behaviors and increased the risk of small-cell lung cancer; it also increased the risk of lung squamous cell carcinoma, but this effect was mediated by smoking [29]. All NSCLC tissues evaluated in our study were ALK-rearranged adenocarcinoma, and only a few patients were current smokers, possibly explaining the beneficial effect of a higher BMI.
Immunological and nutritional markers may be useful in predicting the outcome of Alectinib as a first-line treatment. These data were evaluated at baseline and 3 weeks after the introduction of Alectinib in a retrospective study, and a longer duration of PFS was significantly associated with the baseline platelet-to-lymphocyte ratio, systemic immunoinflammatory index, and prognostic nutritional index [28].
In clinical lung cancer trials, patients have a high incidence of comorbidities, including diabetes mellitus (DM), considered an important component of the metabolic syndrome, and a possible risk factor for lung cancer. Nevertheless, the relationship between the two diseases remains unclear. Wang et al. showed that patients with DM had increased PFS and OS compared with those without, with an mPFS of 12 vs. 6 months and an mOS of 37 vs. 12 months, respectively [30,31].
Metformin, one of the most useful blood glucose-lowering drugs, improved survival in EGFR lung cancer and could be used to overcome HGF resistance to Alectinib. Indeed, in preclinical models, Metformin yielded the disruption of the MET-Gab1 complex and the inhibition of the phosphorylation of Gab1, a key downstream effector of the HGF/MET complex, and reversed Crizotinib resistance through the inhibition of IGF-1R signaling [32,33].
Few patients in this study had DM, and only four received Metformin, but all of them had a longer survival and complete response with Alectinib. However, it could be that MS, constituted by high-BMI and other pathways not known, leads to a beneficial effect on ALK TKIs.
Several trials studied the possible correlation between lung cancer and BMI with controversial results.
High baseline BMI positively correlated with improved lung cancer survival in different stages in different trials, probably because of its role in functional reserve. Meanwhile, the mechanisms of cancer cachexia are not fully understood, and some evidence has suggested that systemic inflammation plays a central role. Many factors could contribute to the pathogenesis of advanced lung cancer-induced cachexia: anorexia, cytokines, and energy and metabolic abnormalities [34,35,36].
Much evidence suggests a certain positive correlation between high-BMI lung cancer patients with immunotherapy but also with surgery, radiotherapy, and some types of chemotherapy. Curiously, prognosis in patients treated with an association of chemotherapy and immunotherapy as first-line treatment, or in the course of the antiangiogenetic agent, was not influenced by BMI. Also, obesity and excess adiposity seem to correlate with poorer survival among patients with NSCLC receiving platinum-based chemotherapy [37,38,39,40].
As previously mentioned, controversial results emerged in the EGFR NSCLC population. In the first-line setting, EGFR TKIs yielded better survival outcomes in overweight patients in two different trials; in the second-line, obesity negatively influenced outcomes. This analysis has never been conducted in ALK-rearranged patients treated with ALK TKIs [25,26,27,41].
On the other hand, BMI could not fully account for body composition because it could not explicate the differences in the ratio of muscle and diverse types of adiposities and the possible influence of endogenous (e.g., sex and race) and exogenous factors (e.g., tobacco consumption) with body habitus [42].
A large, pooled analysis investigated the impact of race, smoking, and sex on the relationship between BMI and OS; female ever-smoker white patients were the most heavily associated with better outcomes with a normal BMI, but this was not the case for underweight/obese patients. Moreover, BMI in Asian patients and never-smokers was not significantly associated with OS. These clinical characteristics are generally typical of the ALK-rearranged population [42].
Lung cancers are known to be aggressive, and patients with advanced disease usually have poorer PS and experience significant weight loss at the time of diagnosis [43]. Notably, in this study, BMI status influenced outcomes independently from basal PS status.
Unfortunately, this study shows some limitations within which these results need to be interpreted. First of all, the retrospective design of the study and the collection of a small number of patients in a single institution may have prevented us from finding a significant correlation between ALK inhibitor outcomes and BMI in the NSCLC population. Moreover, no evaluation of nutritional status has been conducted because data could not be collected uniformly in all the populations, and there is a possible bias connected to nutritional evaluation. Consequently, our study is a future starting point for the evaluation of BMI as a predictive biomarker in the ALK NSCLC population, but results should be interpreted with caution.
Considering the actual challenge of Brigatinib, Alectinib, and Lorlatinib as the best ALK inhibitor according to recent phase III trials results, we believe that it could be useful to identify any possible factor that could predict survival with Alectinib, directing the physicians’ choices of the best-fitting ALK inhibitor for each patient.
Recently, a prospective trial analyzed the influence of Alectinib on body change composition; they demonstrated that Alectinib can cause a significant increase in sarcopenic abdominal obesity soon after initiation. This can lead to many serious metabolic, physical, and mental disturbances in long-term survivors [44].
Based on our results, we suggest that the next step in the development of an effective ALK treatment might be to evaluate the relationship between body size variables (evaluated with impedancemetry tests) and efficacy in the course of ALK inhibitors in NSCLC patients, also considering the influence of weight gain as a common side effect of ALK TKIs.

5. Conclusions

ALK inhibitors represent the gold standard of ALK-rearranged NSCLC treatments, providing significant benefits. We propose this study as a future starting point for a more substantial analysis of the correlation between response to ALK inhibitors and BMI status, also exploiting possible correlation with metabolic syndrome and molecular subtypes of lung cancer. We found a longer OS and PFS during ALK treatment in a small cohort of lung cancer patients with baseline high-BMI, particularly if treated with Alectinib as a first-line treatment. As shown by the multivariate analysis for first-line PFS and OS, the positive effect of BMI was not influenced by basal ECOG PS. However, these data should be further investigated to identify possible clinical factors to personalize the best ALK inhibitors treatment sequence.

Author Contributions

Conceptualization, M.S., A.J.G. and G.G.; methodology, I.S.; software, I.S.; validation, S.C., E.C. and A.J.G.; formal analysis, M.S. and I.S.; investigation, M.S. and A.J.G.; resources, D.S. and E.C.; data curation, M.S., G.G. and S.C.; writing—original draft preparation, M.S.; writing—review and editing, A.J.G. and D.S.; visualization, M.S., S.C. and G.G.; supervision, E.C., A.J.G. and D.S.; project administration, A.J.G.; funding acquisition, D.S. and E.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Sapienza University of Rome, Policlinico Umberto 1 (protocol code 7164; date of approval 10 May 2023).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Written informed consent was obtained from the patient(s) to publish this paper.

Data Availability Statement

The data that support the findings of this study are available from the corresponding authors, M.S. and A.J.G., upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Torre, L.A.; Siegel, R.L. Lung Cancer Statistics. Adv. Exp. Med. Biol. 2016, 893, 1–19. [Google Scholar] [CrossRef]
  2. Ordóñez-Mena, J.M.; Schöttker, B. Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES). Quantification of the smoking-associated cancer risk with rate advancement periods: Meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med. 2016, 14, 62. [Google Scholar] [CrossRef] [Green Version]
  3. Toh, C.K.; Gao, F. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J. Clin. Oncol. 2006, 24, 2245–2251. [Google Scholar] [CrossRef]
  4. Couraud, S.; Souquet, P.J. French Cooperative Intergroup IFCT. BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers. Eur. Respir. J. 2015, 45, 1403–1414. [Google Scholar] [CrossRef] [Green Version]
  5. Melosky, B.; Cheema, P. Canadian perspectives: Update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Curr. Oncol. 2018, 25, 317–328. [Google Scholar] [CrossRef] [Green Version]
  6. Wong, D.W.; Leung, E.L. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115, 1723–1733. [Google Scholar] [CrossRef] [PubMed]
  7. Von Laffert, M.; Warth, A. Multicenter immunohistochemical ALK-testing of non–small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J. Thorac. Oncol. 2014, 9, 1685–1692. [Google Scholar] [CrossRef] [Green Version]
  8. Johung, K.L.; Yeh, N. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J. Clin. Oncol. 2016, 34, 123–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Solomon, B.J.; Mok, T. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371, 2167–2177. [Google Scholar] [CrossRef] [Green Version]
  10. Peters, S.; Camidge, D.R. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N. Engl. J. Med. 2017, 377, 829–838. [Google Scholar] [CrossRef]
  11. Gadgeel, S.; Peters, S. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann. Oncol. 2018, 29, 2214–2222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Camidge, D.R.; Kim, H.R. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 2018, 379, 2027–2039. [Google Scholar] [CrossRef]
  13. Solomon, B.J.; Besse, B. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol. 2018, 19, 1654–1667. [Google Scholar] [CrossRef] [PubMed]
  14. Shaw, A.T.; Bauer. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N. Engl. J. Med. 2020, 383, 2018–2029. [Google Scholar] [CrossRef]
  15. Marinelli, D.; Siringo, M. Non-small-cell lung cancer: How to manage ALK-, ROS1- and NTRK-rearranged disease. Drugs Context 2022, 11, 2022-3-1. [Google Scholar] [CrossRef]
  16. Eckel, R.H.; Grundy, S.M. The metabolic syndrome. Lancet 2005, 365, 1415–1428. [Google Scholar] [CrossRef]
  17. Lohmann, A.E.; Goodwin, P.J. Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. J. Clin. Oncol. 2016, 34, 4249–4255. [Google Scholar] [CrossRef]
  18. Iyengar, N.M.; Gucalp, A. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J. Clin. Oncol. 2016, 34, 4270–4276. [Google Scholar] [CrossRef]
  19. Petrelli, F.; Cortellini, A. Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Netw. Open 2021, 4, e213520. [Google Scholar] [CrossRef]
  20. Ligibel, J.A.; Alfano, C.M. American Society of Clinical Oncology position statement on obesity and cancer. J. Clin. Oncol. 2014, 32, 3568–3574. [Google Scholar] [CrossRef]
  21. Greenlee, H.; Unger, J.M. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol. Biomark. Prev. 2017, 26, 21–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Shepshelovich, D.; Xu, W. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients with SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J. Thorac. Oncol. 2019, 14, 1594–1607. [Google Scholar] [CrossRef] [PubMed]
  23. Gelibter, A.; Occhipinti, M. Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung Cancer Manag. 2020, 9, LMT26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Cortellini, A.; Ricciuti, B. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation. J. Immunother. Cancer 2020, 8, e001403. [Google Scholar] [CrossRef]
  25. Ding, Z.Y.; Chen, Y.Y. Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study. Ann. Oncol. 2019, 30, ii49–ii50. [Google Scholar] [CrossRef]
  26. De Giglio, A.; Di Federico, A. The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib. J. Clin. Oncol. 2021, 39 (Suppl. S15), e21078. [Google Scholar] [CrossRef]
  27. Ono, T.; Igawa, S. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thorac. Cancer 2019, 10, 880–889. [Google Scholar] [CrossRef] [Green Version]
  28. Takeda, T.; Yamada, T. Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics 2021, 11, 2170. [Google Scholar] [CrossRef]
  29. Zhou, W.; Liu, G. Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. Int. J. Cancer 2021, 148, 1077–1086. [Google Scholar] [CrossRef]
  30. Wang, N.F.; Tang, H.M. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer. Chin. Med. J. 2020, 133, 786–791. [Google Scholar] [CrossRef]
  31. Tsai, M.J.; Yang, C.J. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner. Lung Cancer 2014, 86, 137–143. [Google Scholar] [CrossRef] [PubMed]
  32. Han, R.; Jia, Y. Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance. Transl. Lung Cancer Res. 2021, 10, 1277–1291. [Google Scholar] [CrossRef]
  33. Chen, H.; Lin, C. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell Death Dis. 2020, 11, 111. [Google Scholar] [CrossRef] [Green Version]
  34. Abdel-Rahman, O. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. Expert Rev. Respir. Med. 2019, 13, 1029–1035. [Google Scholar] [CrossRef]
  35. Argilés, J.M.; Busquets, S. Cancer cachexia: Understanding the molecular basis. Nat. Rev. Cancer 2014, 14, 754–762. [Google Scholar] [CrossRef]
  36. Zhu, R.; Liu, Z. Updates on the pathogenesis of advanced lung cancer-induced cachexia. Thorac. Cancer 2019, 10, 8–16. [Google Scholar] [CrossRef]
  37. Card, P.; Schussler, O. Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage. Cancers 2020, 12, 266. [Google Scholar] [CrossRef] [Green Version]
  38. Matsunaga, T.; Suzuki, K. Body Mass Index as a Prognostic Factor in Resected Lung Cancer: Obesity or Underweight, Which Is the Risk Factor? Thorac. Cardiovasc. Surg. 2015, 63, 551–557. [Google Scholar] [CrossRef] [PubMed]
  39. Cortellini, A.; Ricciuti, B. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. J. Immunother. Cancer 2022, 10, e004374. [Google Scholar] [CrossRef] [PubMed]
  40. Sutandyo, N.; Hanafi, A.R. Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy. Int. J. Gen. Med. 2023, 16, 85–93. [Google Scholar] [CrossRef]
  41. Chen, Y.M.; Lai, C.H. Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation. Nutrients 2021, 13, 3761. [Google Scholar] [CrossRef] [PubMed]
  42. Jiang, M.; Fares, A.F. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer 2021, 152, 58–65. [Google Scholar] [CrossRef]
  43. Scott, H.R.; McMillan, D.C.; Forrest, L.M.; Brown, D.J.F.; McArdle, C.S.; Milroy, R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 2002, 87, 264–267. [Google Scholar] [CrossRef] [PubMed]
  44. De Leeuw, S.P.; Pruis, M.A.; Sikkema, B.J.; Mohseni, M.; Veerman, G.D.M.; Paats, M.S.; Dumoulin, D.W.; Smit, E.F.; Schols, A.M.J.; Mathijssen, R.H.; et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer. J. Thorac. Oncol. 2023. [Google Scholar] [CrossRef] [PubMed]
Cancers 15 03422 g001 550
Figure 1. Overall survival (a) and progression-free survival of first-line treatment (b) in the overall population according to body mass index (BMI).
Figure 1. Overall survival (a) and progression-free survival of first-line treatment (b) in the overall population according to body mass index (BMI).
Cancers 15 03422 g001
Cancers 15 03422 g002 550
Figure 2. Progression-free survival of Alectinib treatment versus other anti-ALK treatments.
Figure 2. Progression-free survival of Alectinib treatment versus other anti-ALK treatments.
Cancers 15 03422 g002
Cancers 15 03422 g003 550
Figure 3. Progression-free survival according to body mass index (BMI) in patients treated with Alectinib as first-line treatment.
Figure 3. Progression-free survival according to body mass index (BMI) in patients treated with Alectinib as first-line treatment.
Cancers 15 03422 g003
Cancers 15 03422 g004 550
Figure 4. Overall response rate (ORR) measured by RECIST 1.1 Criteria according to body mass index (BMI) in patients treated with Alectinib as first-line treatment. CR = complete response; PD = progression disease; PR = partial response; SD = stable disease.
Figure 4. Overall response rate (ORR) measured by RECIST 1.1 Criteria according to body mass index (BMI) in patients treated with Alectinib as first-line treatment. CR = complete response; PD = progression disease; PR = partial response; SD = stable disease.
Cancers 15 03422 g004
Cancers 15 03422 g005 550
Figure 5. Progression-free survival (PFS) according to body mass index (BMI) in patients treated with other ALK inhibitors (ALKi) versus Alectinib.
Figure 5. Progression-free survival (PFS) according to body mass index (BMI) in patients treated with other ALK inhibitors (ALKi) versus Alectinib.
Cancers 15 03422 g005
Table
Table 1. Clinicopathological characteristics of patients. BMI = body mass index; CNS = central nervous system; DM2 = diabetes mellitus type 2; PS = performance status.
Table 1. Clinicopathological characteristics of patients. BMI = body mass index; CNS = central nervous system; DM2 = diabetes mellitus type 2; PS = performance status.
VariableLevelOverall (N = 40)
SexFemale25 (62.5%)
Male15 (37.5%)
PS013 (32.5%)
125 (62.5%)
22 (5%)
BMILow25 (62.5%)
High15 (37.5%)
Smoking statusNon-smoker21 (52.5%)
Smoker7 (17.5%)
Former smoker12 (30%)
DM2Yes7 (17.5%)
No33 (82.5%)
MetforminYes4 (10%)
No36 (90%)
SteroidsYes21 (52.5%)
No19 (47.5%)
Antiepileptic drugsYes16 (40%)
No24 (60%)
Visceral metastasisYes32 (80%)
No8 (20%)
CNS metastasisYes20 (50%)
No20 (50%)
Number of metastases≤313 (32.5%)
>327 (67.5%)
I lineAlectinib23
Crizotinib10
Brigatinib2
Chemotherapy3
Immunotherapy2
II lineNo treatment23
Alectinib9
Crizotinib2
Brigatinib1
Lorlatinib2
Ceritinib1
Chemotherapy2
III lineNo treatment33
Alectinib2
Lorlatinib4
Chemotherapy1
Table
Table 2. Univariate (a) and multivariate analysis (b) of PFS and OS. Statistically significant values are colored in orange and blue. ALKi = ALK inhibitors; BMI = body mass index; CNS = central nervous system; HR = hazard ratio; OS = overall survival; PFS = progression free survival; PS = performance status.
Table 2. Univariate (a) and multivariate analysis (b) of PFS and OS. Statistically significant values are colored in orange and blue. ALKi = ALK inhibitors; BMI = body mass index; CNS = central nervous system; HR = hazard ratio; OS = overall survival; PFS = progression free survival; PS = performance status.
VariablesPFS Univariate AnalysisOS Univariate Analysis
(a)
Smoking statusHR 1.85 (CI 95% 0.81–4.22) p = 0.15HR 1.36 (CI 95% 0.49–3.81) p = 0.56
Yes vs. No
Age at metastatic stageHR 1.06 (CI 95% 0.98–1.03) p = 0.74HR 1.03 (CI 95% 0.99–1.07) p = 0.22
Number of metastasesHR 1.45 (CI 95% 0.58–3.67) p = 0.43HR 1.02 (CI 95% 0.36–2.91) p = 0.96
Visceral metastasisHR 1.85 (CI 95% 0.54–6.26) p = 0.33HR 3.68 (CI 95% 0.49–27.9) p = 0.21
Yes vs. No
CNS metastasisHR 1.61 (CI 95% 0.72–3.58) p = 0.24HR 1.08 (CI 95% 0.41–2.85) p = 0.87
Yes vs. No
PS0 vs. PS1/2HR 0.22 (CI 95% 0.07–0.65)
p = 0.007		HR 0.21 (CI 95% 0.06–0.71) p = 0.013
BMI high vs. BMI lowHR 0.35 (CI 95% 0.15–0.84)
p = 0.019		HR 0.27 (CI 95% 0.09–0.80) p = 0.020
First-line ALKiHR 2.35 (CI 95% 1.05–5.25) p = 0.038-
Others vs. Alectinib
(b)
PS0 vs. PS1/2HR 0.24 (CI 95% 0.08–0.73) p = 0.012HR 0.15 (CI 95% 0.04–0.55)
p = 0.014
BMI high vs. BMI lowHR 0.39 (CI 95% 0.16–0.96) p = 0.042HR 0.18 (CI 95% 0.05–0.61) p = 0.006
First-line ALKiHR 2.01 (CI 95% 0.89–4.5) p = 0.094-
Others vs. Alectinib
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Siringo, M.; Gentile, G.; Caponnetto, S.; Sperduti, I.; Santini, D.; Cortesi, E.; Gelibter, A.J. Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study. Cancers 2023, 15, 3422. https://doi.org/10.3390/cancers15133422

AMA Style

Siringo M, Gentile G, Caponnetto S, Sperduti I, Santini D, Cortesi E, Gelibter AJ. Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study. Cancers. 2023; 15(13):3422. https://doi.org/10.3390/cancers15133422

Chicago/Turabian Style

Siringo, Marco, Gabriella Gentile, Salvatore Caponnetto, Isabella Sperduti, Daniele Santini, Enrico Cortesi, and Alain Jonathan Gelibter. 2023. "Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study" Cancers 15, no. 13: 3422. https://doi.org/10.3390/cancers15133422

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop